Professor Lars Gustafsson and Magnus Persson discover that endogenous NO can be measured in the exhaled air in animals and humans. 

The research group launches a comprehensive program to study the importance of NO in the pulmonary and cardiovascular systems and the potential of the discovery of NO for future diagnostics and therapy. 

Christofer Adding and Per Agvald and towards the end of the period Kristofer Nilsson. Dag Linnarsson is linked to the group through different research collaborations. Disease animal models for various types of Pulmonary hypertension e.g pulmonary embolism are developed. It is concluded that NO can counteract Pulmonary Hypertension and increase survival. 

A new method to create compositions capable of delivering NO via intravenous infusion is formulated and the patent processes begin.

The start